Presently, the resolution of artificial vision and sensory substitution devices provide what is termed “ultra-low vision,” allowing for crude perceptions of larger, high contrast objects.
9,15,16 Because current artificial vision technology cannot recapitulate the complexity of normal vision, traditional clinical methods of assessing visual function are not appropriate. Establishing objective methods to determine improvement in function is vital to gauge performance improvement, to compare subsequent device iterations, and for regulatory approval. Moreover, if such outcomes can be standardized, comparisons between different types of artificial vision devices would be facilitated
17 (
www.nei.nih.gov/news/meetings/fDA_2011.asp). Several studies have used various techniques such as light detection, square pointing, object recognition, mobility tasks, and resolution as ways to show improvement over baseline for patients using artificial vision (Friberg TNA, et al.
IOVS. 2011;52:ARVO E-Abstract 109; Nau A, et al.
IOVS. 2011;52:ARVO E-Abstract 461).
4,18–21 At the present time, there is no agreement among researchers working in these nascent fields regarding the most appropriate outcomes tools. Some aspect of functional ability should be considered, and is recognized in the field of low vision.
22 In addition, good arguments can be made that outcomes assessments need to go a step further to incorporate patient reported outcomes and quality of life measures.
23 To date, there has not been a comprehensive attempt to systematically measure the sensory experiences that are enabled by visual sensory substitution devices. Interesting questions arise as to whether perceptions mediated through nonstandard pathways produce sensations that can be measured with tests designed to quantify vision, per se. In spite of the proven activation of visual cortex with sensory substitution, bootstrapping visual information onto an alternative afferent stream could elicit atypical or aberrant outputs. There is limited proof beyond anecdotal reports that any improvement can be conferred by use of these devices, partially because there are no accepted outcomes measures with which to demonstrate efficacy. Additional gaps in knowledge include whether the existing outcomes measures used for some retinal implant chips (also producing states of ultra-low vision) might be useful for sensory substitution, as well as also how to set up and administer the tests. This paper describes our efforts to systematically investigate whether existing, validated tests of ultra-low vision would need to be modified when used in the context of sensory substitution.